CureVac AG :
Curevac is a private German mRNA company with a diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19) provides further technology validation. Other companies in the space: MRNA, TBIO, BNTX.
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
Ph1 readout mid-2021
Ph2 initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
Phase l or ll
Anti-infectives, Antivirals, Autoimmune, Oncology
Platform Technology, Vaccine
Tübingen, Baden-Wurttemberg 72076
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.